Litigation Details for Cubist Pharmaceuticals LLC v. Actavis LLC (D. Del. 2015)

« Back to Dashboard

Cubist Pharmaceuticals LLC v. Actavis LLC (D. Del. 2015)

Docket		Date Filed	2015-12-29
Court	District Court, D. Delaware	Date Terminated	2016-06-06
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,468,967; 6,852,689; 8,058,238; 8,129,342
Link to Docket	External link to docket

Details for Cubist Pharmaceuticals LLC v. Actavis LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-12-29				External link to document
2015-12-28	10		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,468,967 B1; 6,852,689 B2; 8,058,238… 2015 6 June 2016 1:15-cv-01214 830 Patent None District Court, D. Delaware	External link to document
2015-12-28	4		the Commissioner of Patents and Trademarks for Patent/Trademark Numbers: 6,468,967 B1; 6,852,689 B2; 8,058,238… 2015 6 June 2016 1:15-cv-01214 830 Patent None District Court, D. Delaware	External link to document

Cubist Pharmaceuticals LLC v. Actavis LLC, 1:15-cv-01214: Litigation Summary and Patent Analysis

Last updated: September 8, 2026

Cubist Pharmaceuticals LLC sued Actavis in the U.S. District Court for the District of Delaware after Actavis filed an abbreviated new drug application seeking approval to market a generic version of Cubist’s daptomycin product, Cubicin. The case was an ANDA patent action under the Hatch-Waxman Act. The public docket does not show a reported merits judgment establishing infringement or invalidity. The proceeding ended through a dismissal, consistent with a confidential settlement or other negotiated resolution. The case therefore had greater settlement and launch-timing significance than precedential value. [1]

What drug and product did Cubist seek to protect?

The litigation concerned daptomycin for injection, marketed by Cubist as Cubicin. Daptomycin is a cyclic lipopeptide antibiotic approved for serious gram-positive bacterial infections, including complicated skin and skin-structure infections and Staphylococcus aureus bacteremia, including right-sided infective endocarditis. [2]

Product and regulatory profile

Item	Information
Brand	Cubicin
Active ingredient	Daptomycin
Dosage form	Lyophilized powder for injection
Administration	Intravenous
NDA holder at relevant time	Cubist Pharmaceuticals, later associated with Merck
Regulatory pathway challenged	Actavis ANDA
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:15-cv-01214
Statutory basis	Hatch-Waxman artificial-infringement action under 35 U.S.C. § 271(e)(2)
Patent dispute type	ANDA certification and generic-entry litigation

Cubist was acquired by Merck in 2015. The acquisition transferred commercial control of Cubicin and related patent enforcement activity to Merck’s pharmaceutical organization. [3]

What patents protected Cubicin in the Actavis litigation?

The case formed part of the broader Cubicin patent estate, which included composition, dosage-regimen, formulation, and method-of-use patents. The core daptomycin patent was U.S. Patent No. 6,468,967, which covered daptomycin compositions and related subject matter. That patent was litigated extensively against generic manufacturers and expired in 2016, subject to applicable patent-term adjustments and pediatric exclusivity. [4]

The later Cubicin estate included patents directed to administration and clinical-use parameters. Public records associated with Cubicin identify patents including U.S. Patent Nos. 8,835,358 and 8,883,829. These patents were more relevant to post-composition exclusivity and could affect a generic applicant’s labeling strategy even after the basic compound patent expired. [5]

Patent categories relevant to the dispute

Patent category	Commercial purpose	Generic-defense issue
Composition patents	Protect daptomycin or defined daptomycin compositions	Invalidity, noninfringement, expiration
Dosage-regimen patents	Protect dose, frequency, or treatment duration	Section viii carve-out and induced-infringement risk
Formulation patents	Protect injectable or reconstituted formulations	Formulation differences and claim construction
Method-of-use patents	Protect treatment of specified bacterial infections	Label carve-outs and physician-use evidence
Manufacturing patents	Protect production or purification processes	Usually less directly relevant to ANDA approval unless product claims are implicated

The Actavis case should not be read as a determination that every listed Cubicin patent was infringed. In an ANDA action, the filing itself creates an artificial act of infringement for purposes of adjudicating whether the proposed product would infringe the asserted patents. It does not establish commercial infringement by an already marketed product.

What was the procedural history of Cubist v. Actavis?

Cubist filed the action in the District of Delaware in 2015 after receiving notice of Actavis’s ANDA certification. The litigation followed the standard Hatch-Waxman sequence:

1. Actavis submitted an ANDA for generic daptomycin.
2. Actavis provided patent certifications addressing Cubist’s Orange Book-listed patents.
3. Cubist filed suit within the statutory window.
4. FDA approval was subject to the statutory litigation stay, generally lasting 30 months unless modified or terminated earlier.
5. The parties litigated patent and claim-construction issues.
6. The case was ultimately dismissed without a public merits opinion.

The docket number is 1:15-cv-01214. The case was assigned to the District of Delaware, a principal forum for pharmaceutical patent litigation. The public docket does not identify a Federal Circuit appeal or a published trial judgment resolving validity and infringement. [1]

Was there a 30-month FDA stay?

The filing of a timely Paragraph IV action ordinarily triggers a 30-month stay of final FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii). The stay can end earlier through a court decision, dismissal, settlement terms, or other statutory events. The public docket does not establish a publicly disclosed, case-specific alteration of the statutory stay.

The practical effect was to delay Actavis’s approval while the patent dispute remained active. The litigation was therefore commercially relevant even without a final trial judgment.

What were Actavis’s likely Paragraph IV positions?

Actavis’s ANDA certifications would have required it to challenge at least one Orange Book-listed patent or state that the relevant patent was not infringed by the proposed generic product. The principal legal theories in this type of dispute are:

• The asserted claims were invalid for obviousness, lack of written description, lack of enablement, anticipation, or indefiniteness.
• The ANDA product did not infringe the asserted composition or formulation claims.
• The proposed label did not induce infringement of method-of-use claims.
• A section viii statement could carve out patented uses from the generic label.

Why the label mattered

Daptomycin has multiple approved uses and dosing regimens. Method-of-use patents can be avoided through a label that omits the patented indication or dosing instruction, although the legal analysis depends on the complete labeling, product marketing, physician behavior, and the scope of the claims.

For Cubist, the principal commercial risk was that a generic manufacturer could enter with a label covering unpatented uses while physicians still used the product for patented indications. For Actavis, the principal risk was an induced-infringement finding based on the generic label, promotional materials, or foreseeable physician use.

What was the litigation outcome?

The public record does not show a final judgment that Actavis infringed a Cubist patent or that the asserted patents were invalid. The action was dismissed rather than resolved through a published trial opinion. The dismissal indicates that the parties ended the dispute, but it does not disclose the commercial terms.

Settlement terms and generic launch date

No public settlement terms establish:

• Actavis’s agreed launch date;
• whether Actavis received a licensed entry date;
• whether the agreement included a supply arrangement;
• whether the settlement contained a no-authorized-generic provision;
• whether Actavis could launch at risk;
• whether the parties exchanged value; or
• whether the agreement involved other daptomycin litigation.

Accordingly, the case does not provide a public basis for assigning Actavis a definitive generic launch date. The absence of a reported judgment does not mean the patents were upheld. It means the commercial resolution was not adjudicated in a published decision. [1]

What was the Orange Book status of Cubicin?

Cubicin’s Orange Book protection consisted of multiple patent listings with different legal functions. The earliest compound protection was materially weaker by the time of the Actavis case because the principal daptomycin patent was approaching or had reached expiration. Later patents could still affect particular labels, formulations, or uses. [5]

Orange Book and exclusivity analysis

Protection	Relevance in 2015
Daptomycin composition patent	Near expiration or expired, reducing broad product protection
Method-of-use patents	Potentially relevant to label scope and induced infringement
Formulation patents	Potentially relevant to injectable product design
Regulatory exclusivity	Separate from patent rights and dependent on the NDA and approval history
Pediatric exclusivity	Could extend certain listed patent or exclusivity periods by six months if applicable

Patent expiration and FDA exclusivity are separate. Expiration of a composition patent does not automatically eliminate later method or formulation patents. Conversely, a patent does not create FDA exclusivity unless the statutory requirements for exclusivity are met.

How strong was Cubist’s patent estate?

Cubist’s estate was strong in breadth but weaker in timing by 2015.

Strengths

• The estate originated from a commercially important branded antibiotic.
• The core product had established clinical use and significant sales.
• Multiple patents could create overlapping barriers involving composition, dosing, formulation, and use.
• Hatch-Waxman litigation delayed approval even when a generic applicant challenged the estate.
• Method patents could preserve some protection after the compound patent expired.

Weaknesses

• The principal daptomycin composition patent was near expiration.
• Method-of-use patents are vulnerable to section viii carve-outs.
• Generic applicants can design around formulation claims.
• A dismissal without judgment leaves no public precedent confirming claim validity.
• The product’s broad commercial market made partial-label generic entry more feasible.

The estate therefore provided meaningful short-term negotiating leverage but less durable protection than a later-stage biologic estate or a platform with enforceable manufacturing and formulation barriers.

What generic entry risks existed for Cubicin?

The principal entry scenarios were:

Scenario	Effect on Cubist/Merck
Full-label generic approval	Broad price pressure across daptomycin indications
Skinny-label approval	Competition in unpatented uses while preserving some branded uses
Delayed negotiated entry	Continued revenue protection until the agreed date
At-risk launch	Immediate exposure to damages and possible injunction proceedings
Multiple generic approvals	Rapid erosion of net price and market share

Daptomycin is a small-molecule injectable, so biosimilar risk did not apply. The relevant competitors were ANDA applicants, not biosimilar applicants under the Public Health Service Act.

Manufacturing complexity offered some practical friction because sterile injectable products require validated aseptic production, regulatory compliance, and reliable supply. Those barriers are commercial and regulatory rather than equivalent to enforceable patent exclusivity.

Which companies challenged Cubicin patents?

Cubicin was subject to broader generic competition and patent litigation involving several ANDA manufacturers, including Actavis and Hospira. The specific 1:15-cv-01214 action should be analyzed separately from parallel cases because different defendants may have filed different certifications, proposed different labels, or asserted different noninfringement and invalidity arguments.

The Hospira litigation produced reported Federal Circuit decisions involving Cubicin patent claims, giving that litigation greater precedential significance than the Actavis docket. Those decisions should not be treated as the holding of the Actavis case. [4]

What was the commercial impact of the case?

Cubicin was a major product for Cubist and later Merck. Generic entry risk affected both revenue and valuation because daptomycin faced a predictable post-patent price decline. The commercial impact depended on whether Actavis obtained approval for all indications, whether other ANDA applicants entered, and whether the settlement allowed entry before the full expiration of later-listed patents.

The case’s revenue exposure was therefore tied to three variables:

1. The timing of broad generic approval.
2. The scope of any label carve-out.
3. The number and launch timing of competing ANDA products.

The public docket does not disclose a case-specific damages amount or settlement payment. No reliable revenue figure should be attributed solely to this action.

How does Cubicin compare with biologic exclusivity disputes?

Cubicin is a small-molecule antibiotic. It did not face biosimilar litigation under the biologics pathway. Its generic competitors could rely on an ANDA, allowing the FDA to evaluate pharmaceutical equivalence and bioequivalence rather than requiring a biosimilar showing under section 351(k).

That distinction made patent litigation more central to launch timing. For biologics, regulatory exclusivity, interchangeability, manufacturing comparability, and patent-listing procedures can create additional barriers. For Cubicin, the central legal issues were Orange Book listings, Paragraph IV certifications, claim scope, label carve-outs, and the 30-month stay.

Key Takeaways

• Cubist Pharmaceuticals sued Actavis in Delaware over an ANDA for generic daptomycin, the active ingredient in Cubicin.
• The case was filed as a Hatch-Waxman artificial-infringement action under 35 U.S.C. § 271(e)(2).
• Cubicin’s estate included composition, formulation, dosage-regimen, and method-of-use protection.
• The core daptomycin composition patent was near expiration by the time of the 2015 case.
• Later method and formulation patents created narrower but commercially relevant barriers.
• The public record does not show a final merits judgment or a published finding of infringement or invalidity.
• The case ended through dismissal, with no publicly disclosed settlement terms or definitive Actavis launch date.
• Biosimilar risk was not applicable because daptomycin is a small-molecule drug.
• The principal commercial risk was rapid price erosion from one or more ANDA-approved generic injectables.

FAQs

Did Actavis win Cubist v. Actavis?

The public docket does not show a merits judgment awarding Actavis a victory. The case ended by dismissal, which is consistent with a negotiated resolution but does not determine patent validity or infringement.

Was Cubicin protected by a biologic patent estate?

No. Cubicin contains daptomycin, a small-molecule active ingredient. Generic competition proceeds through the ANDA pathway rather than the biosimilar pathway.

Did the Actavis case invalidate U.S. Patent No. 6,468,967?

No published decision in the identified docket establishes that result. The patent was separately litigated in other proceedings and approached expiration independently of the dismissal in the Actavis case.

Could Actavis launch a skinny-label daptomycin product?

Potentially, subject to FDA approval and the scope of the asserted method-of-use patents. A skinny-label strategy would omit patented uses but could still expose the manufacturer to induced-infringement allegations based on labeling or commercial conduct.

Did Cubist disclose the value of its settlement with Actavis?

No public docket material establishes the financial or commercial terms of the resolution.

References

1. U.S. District Court for the District of Delaware. (2015–2017). Cubist Pharmaceuticals LLC v. Actavis LLC, No. 1:15-cv-01214. PACER docket materials.

2. U.S. Food and Drug Administration. (2016). Cubicin (daptomycin for injection) prescribing information. FDA.

3. Merck & Co., Inc. (2015). Merck completes acquisition of Cubist Pharmaceuticals. Merck press release.

4. Cubist Pharmaceuticals, Inc. v. Hospira, Inc., 805 F.3d 1112 (Fed. Cir. 2015).

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. FDA.